Fox Chase patients may be eligible to receive third COVID-19 vaccine dose – Read More

MENU

International Study Identifies New Mesothelioma Predisposition Gene

May 19, 2021

Dr. Joseph Testa, supervisor of the study and senior member of the Cancer Signaling and Epigenetics Program at Fox ChaseDr. Joseph Testa, supervisor of the study and senior member of the Cancer Signaling and Epigenetics Program at Fox Chase

PHILADELPHIA (May 19, 2021)—In a study released today, researchers at Fox Chase Cancer Center and a team of international researchers identified a mutated gene called LRRK2 that may indicate a predisposition to malignant mesothelioma.  

Malignant mesothelioma is an aggressive type of cancer that typically arises in individuals who have been exposed to asbestos. LRRK2 is a gene involved in regulating responses in immune cells in the brain.

“We found that most mesothelioma patients from high-risk cancer families have one to four inherited mutations in cancer-related genes that may predispose them to the carcinogenic effects of asbestos,” said Joseph R. Testa, PhD, FACMG, who conceived and supervised the study. Testa is professor and senior member in the Cancer Signaling and Epigenetics Program at Fox Chase; the study was conducted with other researchers at Fox Chase and at research centers in Italy and North Carolina.

“Nearly 50% of these mesothelioma patients have bona fide pathogenic mutations that are expected to contribute to disease susceptibility due to their predicted adverse impact on processes such as DNA repair and chromatin modification,” said Testa, who is also the Carol & Kenneth E. Weg Chair in Human Genetics at Fox Chase.

The goal of the research was to use whole genome sequencing to determine the types and frequency of germline (heritable) gene variants present in 13 malignant mesothelioma patients. The patients in this study were selected from a series of 141 asbestos-exposed mesothelioma patients with a family history of cancer but without a germline mutation in the BAP1 gene. One other asbestos-exposed patient from Italy had a family history that included six siblings who developed mesothelioma.

BAP1 is a tumor suppressor gene that is commonly mutated in familial mesothelioma cases; these mutations have been shown to contribute to malignant mesothelioma susceptibility. The researchers found that six of the 13 new mesothelioma patients exhibited one or more predicted pathogenic mutations in genes other than BAP1.

“Remarkably, in our study, Mitchell Cheung, PhD, first author on the study, found that two of the patients with mutations, including the one from Italy, affected a gene that has previously been strongly linked to Parkinson’s disease. When Mitchell searched The Cancer Genome Atlas database of genetic alterations in mesothelioma, he found that this gene is mutated in only about 3% of non-hereditary mesotheliomas,” Testa said. Cheung is an assistant research professor in Testa’s lab.

“Thus, we were surprised that expression of the LRRK2 gene was lost in 60% of the approximately 30 primary mesothelioma tumors and mesothelioma cell lines that we subsequently examined,” Testa added.

“Collectively, our data suggest that in addition to being a cancer predisposition gene, loss of expression of this newly recognized tumor suppressor gene is a frequent finding in mesothelioma and may serve as a biomarker for identifying those patients most likely to benefit from specific therapies that target pathways affected by LRRK2 loss.”

The researchers are now working to get funding to investigate how this specific gene becomes down-regulated in mesothelioma patients and how its loss of function contributes to the development of tumors.

The study, “Novel LRRK2 Mutations and Other Rare, Non-BAP1-Related Candidate Tumor Predisposition Gene Variants in High-Risk Cancer Families with Mesothelioma and Other Tumors,” was published in the journal Human Molecular Genetics.

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

 

For more information, call 888-369-2427

Connect with Fox Chase